Milestone Pharmaceuticals (MIST) Stock Drops -17.8% Over 30 Days Amid Ongoing Challenges
Key Takeaways
- MIST declined roughly 17.8% over the last 30 days, closing near $0.65 on October 23, 2026, down from about $0.79 a month earlier.
- The move extends a longer slide: the stock is down approximately 44% over the last quarter and trades near its 52-week lows.
- Persistent operating losses, an active at-the-market equity program, and a dilutive financing overhang have continued to weigh on investor sentiment.
- CARDAMYST (etripamil) nasal spray is FDA-approved for paroxysmal supraventricular tachycardia (PSVT), but commercial revenue remains modest during the early launch phase.
- Milestone is advancing the Phase 3 ReVeRA-301 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR), with enrollment now underway in the U.S., Canada, and Europe.
- Elevated short interest and broad risk-off positioning across small-cap biotech have amplified the downside pressure.
- For additional data on this ticker, explore Milestone Pharmaceuticals' Price Targets, Earnings, and Forecast pages.
Company Background and Pipeline Overview
Milestone Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on cardiovascular medicines, with operations based in Montreal and Charlotte. Its lead product is CARDAMYST (etripamil) nasal spray, a novel, rapid-onset calcium channel blocker approved by the U.S. Food and Drug Administration for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. It is positioned as a self-administered, on-demand treatment intended to reduce reliance on hospital-based care. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Beyond the approved PSVT indication, Milestone is developing etripamil for AFib-RVR through the Phase 3 ReVeRA-301 trial and for pediatric PSVT in Phase 2 studies. The company has also secured regulatory and commercial pathways outside the United States, including an approval of etripamil in China through partner Everest Medicines and a marketing application filed with the European Medicines Agency. Investors follow the stock for the commercial ramp of CARDAMYST, the larger AFib-RVR opportunity, and the company's ability to fund operations while losses remain substantial.
Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, MIST fell from a closing price of approximately $0.79 to about $0.65, a decline of roughly 17.8%. The move has been choppy rather than event-driven, with the stock grinding lower alongside elevated trading volume on several down days.
The quarterly picture is even more pronounced. Three months earlier, MIST closed near $1.16, meaning the stock has lost about 44% over the last quarter. That places the shares near their 52-week lows and well below the year's earlier levels, extending a downtrend that has persisted for most of 2026.
Drivers Behind the Recent 30-Day Decline
No single binary event explains the recent decline; instead, a combination of structural pressures has kept selling momentum intact. Milestone reported second-quarter results in August 2026, posting a wider-than-expected loss per share, and its CARDAMYST commercial revenue remains small relative to its cost base. The company's ongoing at-the-market equity offering and a materially higher share count compared with a year ago continue to create an overhang, as investors weigh potential future dilution against limited near-term revenue.
Sentiment has also been pressured by elevated short interest and broader risk-off positioning in small-cap biotech, where cash-runway and financing concerns have prompted sustained de-risking. Positive developments during the period—including Cantor Fitzgerald initiating coverage with an Overweight rating and a $3 price target in late August, approval of etripamil by China's National Medical Products Administration, enrollment of the first European patient in ReVeRA-301, and planned data presentations at upcoming cardiology conferences—have not been enough to reverse the downward trend.
Broader Factors Influencing the Quarterly Slide
The quarterly decline reflects a larger multi-month narrative rather than a single catalyst. Milestone has been funding a commercial launch and an expanding clinical pipeline while still generating losses and negative cash flow. Its share count has risen substantially over the past year as the company has used equity-based financing, diluting existing holders. With revenue only beginning to ramp and development costs continuing, investors have repriced the stock lower as financing risk and the pace of the commercial launch have remained front of mind.
The decline has also tracked a broader pullback in speculative biotech names, where risk tolerance has contracted. Against that backdrop, the stock's slide from about $1.16 to roughly $0.65 over the quarter reflects persistent selling pressure rather than a sharp one-day shock.
Key Areas to Watch Going Forward
Looking ahead, investors will likely focus on the pace of CARDAMYST commercial adoption and expanding payer and formulary coverage, which directly affect revenue growth. Milestone's quarterly results—with its next report expected around November 2026—will provide updated guidance on spending, cash position, and launch metrics.
Clinical milestones also matter: progress in the Phase 3 ReVeRA-301 trial for AFib-RVR, which the company is pursuing through a supplemental new drug application pathway, represents the largest expansion opportunity. Data presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 and American Heart Association (AHA) Scientific Sessions 2026 conferences may offer additional insights. Finally, financing and balance-sheet dynamics, including any future equity raises, cash runway, and the stock's level relative to exchange listing thresholds, remain key risk factors for investors to monitor.
Using Tickeron Tools for Market Insights
In my own analysis, I frequently review Tickeron’s Trending AI Robots to identify systematic strategies that align with current market conditions. The page features a curated selection of top-performing automated bots across thousands of tickers, making it easier to compare approaches by holding period, risk profile, and historical results without sifting through every option. This resource serves as a practical starting point for traders looking to incorporate data-driven ideas into their process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MIST in upward trend: price may jump up because it broke its lower Bollinger Band on October 23, 2026
MIST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 33 of 37 cases where MIST's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MIST's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MIST just turned positive on October 12, 2026. Looking at past instances where MIST's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIST advanced for three days, in 220 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIST as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for MIST entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.430) is normal, around the industry mean (3.035). P/E Ratio (-0.997) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (44.843) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. MIST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturer of cardiovascular medicines
Industry Biotechnology
Advertisement